
Senior Director, Medical Monitor, Hematology–Oncology
Location: New York, NY (Hybrid)
Department: Clinical Development – Clinical Sciences
Reports to: Chief Medical Officer
About Cellectis
Cellectis is a clinical‑stage biotechnology company developing off‑the‑shelf UCART® allogeneic CAR‑T therapies to create a future where gene‑edited cell therapies are accessible to all patients who need them. Driven by innovation, scientific rigor, and a commitment to patients, we are advancing a pipeline designed to transform the treatment landscape across hematologic malignancies.
We are seeking a Senior Director, Medical Monitor with deep Hematology/Oncology expertise to join our Clinical Sciences team and help shape the next generation of UCART therapies.
The Senior Director, Medical Monitor serves as a senior medical and scientific leader within the Clinical Development organization. In this role, you will guide clinical strategy, lead medical oversight for clinical studies, and partner cross‑functionally to ensure the successful execution of Cellectis’ clinical‑stage programs. You will be a key contributor to trial design, safety evaluation, regulatory interactions, and data interpretation across the UCART portfolio.
Key Responsibilities
Education and Experience
Core Competencies
Compensation Range: $240k-275k

Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.
With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.
Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC.
We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.
At Cellectis, we are committed to a cure.
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/
Follow our other social media account on X.
(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.
TALEN® is a registered trademark owned by the Cellectis Group.